This four day program is divided into a two-day symposium with lectures presented by world class scientists in the field of immuno-oncology and with representation by all the main multiplex [….]
Under the joint research collaboration agreement, which covers activities from candidate drug generation up until IND-enabling studies, each company will be responsible for its own costs. The parties may continue further development of the resulting bispecific molecule under a separate co-development collaboration and licensing agreement.